Mitsubishi Tanabe Pharma Corporation

Termination of License Agreement with Cytochroma for MT-2832 (Generic Name: Lunacalcipol) as a Treatment for Secondary Hyperparathyroidism

Osaka, Japan, June 1, 2012--- Mitsubishi Tanabe Pharma Corporation (President & CEO: Michihiro Tsuchiya) announced today that the company and Cytochroma Inc. (Head Office: Ontario, Canada; CEO: Charles Bishop) have mutually agreed to terminate the license agreement that was executed in July of 2008 under which Cytochroma granted Mitsubishi Tanabe an exclusive license in the United States (US) and Asia, including Japan to develop MT-2832 (generic name: lunacalcipol), a novel vitamin D compound, as a treatment for secondary hyperparathyroidism in dialysis patients. In view of the recent changes in US market dynamics relating to dialysis treatment, Mitsubishi Tanabe Pharma has reconsidered its product strategy and has decided not to continue development of MT-2832.

Upon termination of the agreement, Mitsubishi Tanabe Pharma will return to Cytochroma the rights to develop and market lunacalcipol in the US and Asian territories.

<<Contact for Inquiries>>
Corporate Communications Department
Phone: +81-6-6205-5211